Prasugrel Explained

Prasugrel, sold under the brand name Effient in the US, Australia and India, and Efient in the EU) is a medication used to prevent formation of blood clots. It is a platelet inhibitor and an irreversible antagonist of P2Y12 ADP receptors and is of the thienopyridine drug class. It was developed by Daiichi Sankyo Co. and produced by Ube and marketed in the United States in cooperation with Eli Lilly and Company.

Prasugrel was approved for use in the European Union in February 2009,[1] and in the US in July 2009, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).[2]

Medical uses

Prasugrel is used in combination with low dose aspirin to prevent thrombosis in patients with acute coronary syndrome, including unstable angina pectoris, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI), who are planned for treatment with PCI. Prasugrel is associated with a higher bleeding risk compared to clopidogrel but has demonstrated superiority in reducing the composite endpoint of death, recurrent myocardial infarctions and stroke.[3]

Prasugrel does not change the risk of death when given to people who have had a STEMI or NSTEMI.

Given the risk of bleeding, prasugrel should not be used in people who are older than 75 years, who have low body weight or a history of transient ischemic attacks or strokes.[3] [4] The initiation of prasugrel before coronary angiography outside the context of primary PCI is not recommended.[5] [6]

Approval status

The drug was introduced to clinical practice in Canada in 2010 [7] but was subsequently withdrawn by the manufacturer in 2020 as a "business decision". This has left a gap in the management of high-risk patients in certain situations in Canada where Effient was the drug of choice.[8]

Contraindications

Prasugrel should not be given to people with active pathological bleeding, such as peptic ulcer or a history of transient ischemic attack or stroke, because of higher risk of stroke (thrombotic stroke and intracranial hemorrhage).[9]

Adverse effects

Adverse effects include:

Interactions

Prasugrel has a low potential for interactions. It may, for example, be used with proton pump inhibitors to reduce the risk of gastrointestinal bleeding without loss of its antiplatelet effect.[10] [11] [12] [13]

Pharmacology

Mechanism of action

Prasugrel is a member of the thienopyridine class of ADP receptor inhibitors, like ticlopidine (trade name Ticlid) and clopidogrel (trade name Plavix). These agents reduce the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. Prasugrel inhibits platelet aggregation more rapidly, more consistently, and to a greater extent than clopidogrel.[14] [15] The TRITON-TIMI 38 study compared prasugrel with clopidogrel, and showed that prasugrel reduced rates of ischaemic events, but increased bleeding risk. Overall mortality rates were similar for each drug.[3]

Clopidogrel, unlike prasugrel, was issued a black box warning from the FDA on March 12, 2010, as the estimated 2–14% of the US population who have low levels of the CYP2C19 liver enzyme needed to activate clopidogrel may not get the full effect. Tests are available to predict if a patient would be susceptible to this problem or not.[16] [17] Unlike clopidogrel, prasugrel is effective in most individual with the exception in patients over the age of 75, weight under 60 kg, and patients with a history of stroke or TIA due to increased risk of bleeding,[18] [3] although several cases have been reported of decreased responsiveness to prasugrel.[19] It has been suggested that the decreased responsiveness observed in prasugrel is likely due to its low but significant frequency of High Platelet Reactivity (HPR).[20]

Pharmacodynamics

Prasugrel produces inhibition of platelet aggregation to 20 μM or 5 μM ADP, as measured by light transmission aggregometry.[21] Following a 60-mg loading dose of the drug, about 90% of patients had at least 50% inhibition of platelet aggregation by one hour. Maximum platelet inhibition was about 80%. Mean steady-state inhibition of platelet aggregation was about 70% following three to five days of dosing at 10 mg daily after a 60-mg loading dose.Platelet aggregation gradually returns to baseline values over five to 9 days after discontinuation of prasugrel, this time course being a reflection of new platelet production rather than pharmacokinetics of prasugrel. Discontinuing clopidogrel 75 mg and initiating prasugrel 10 mg with the next dose resulted in increased inhibition of platelet aggregation, but not greater than that typically produced by a 10-mg maintenance dose of prasugrel alone. Increasing platelet inhibition could increase bleeding risk. The relationship between inhibition of platelet aggregation and clinical activity has not been established.[22]

Pharmacokinetics

Prasugrel is a prodrug and is rapidly metabolized by carboxylesterase 2 in the intestine and carboxylesterase 1 in the liver to a likewise inactive thiolactone, which is then converted by CYP3A4 and CYP2B6, and to a minor extent by CYP2C9 and CYP2C19, to a pharmacologically active metabolite (R-138727).[23] [24] R-138727 has an elimination half-life of about 7 hours (range 2 h to 15 h). Healthy subjects, patients with stable atherosclerosis, and patients undergoing PCI show similar pharmacokinetics.

Chemistry

Prasugrel has one chiral atom. It is used in racemic form as the hydrochloride salt, which is a white powder.

Further reading

External links

Notes and References

  1. Web site: European Public Assessment Report for Efient. EMA. 2009.
  2. Baker WL, White CM . Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes . American Journal of Cardiovascular Drugs . 9 . 4 . 213–229 . 2009 . 19655817 . 10.2165/1131209-000000000-00000 . 37160513 .
  3. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM . 6 . Prasugrel versus clopidogrel in patients with acute coronary syndromes . The New England Journal of Medicine . 357 . 20 . 2001–2015 . November 2007 . 17982182 . 10.1056/NEJMoa0706482 . free .
  4. Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, Woodruffe S, Kerr A, Branagan M, Aylward PE . 6 . National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016 . The Medical Journal of Australia . 205 . 3 . 128–133 . August 2016 . 27465769 . 10.5694/mja16.00368 . 13014429 .
  5. Bellemain-Appaix A, Kerneis M, O'Connor SA, Silvain J, Cucherat M, Beygui F, Barthélémy O, Collet JP, Jacq L, Bernasconi F, Montalescot G . 6 . Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis . BMJ . 349 . aug06 2 . g6269 . October 2014 . 25954988 . 4208629 . 10.1136/bmj.g6269 .
  6. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P . 6 . Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes . The New England Journal of Medicine . 369 . 11 . 999–1010 . September 2013 . 23991622 . 10.1056/NEJMoa1308075 . 205095981 . free .
  7. Web site: Product information -Effient . . 2021 . Health Canada . February 18, 2021.
  8. Lordkipanidzé M, Marquis-Gravel G, Tanguay JF, Mehta SR, So DY . Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada . CJC Open . 3 . 6 . 814–821 . June 2021 . 34169260 . 8209390 . 10.1016/j.cjco.2020.11.021 . free .
  9. Web site: Effient (prasugrel hydrochloride) Prescribing Information. September 2011. U.S. Food and Drug Administration (FDA). 2019-12-16. 2017-01-18. https://web.archive.org/web/20170118091848/http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm275490.htm. dead.
  10. John J, Koshy SK . Current oral antiplatelets: focus update on prasugrel . Journal of the American Board of Family Medicine . 25 . 3 . 343–349 . 2012 . 22570398 . 10.3122/jabfm.2012.03.100270 . free .
  11. Demcsák A, Lantos T, Bálint ER, Hartmann P, Vincze Á, Bajor J, Czopf L, Alizadeh H, Gyöngyi Z, Márta K, Mikó A, Szakács Z, Pécsi D, Hegyi P, Szabó IL . 6 . PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis . Frontiers in Physiology . 9 . 1550 . 2018-11-19 . 30510515 . 6252380 . 10.3389/fphys.2018.01550 . free .
  12. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD . 6 . Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials . Lancet . 374 . 9694 . 989–997 . September 2009 . 19726078 . 10.1016/S0140-6736(09)61525-7 . 205956050 .
  13. Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Bhatt DL . 6 . Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial . The American Journal of Medicine . 129 . 9 . 1002–1005 . September 2016 . 27143321 . 10.1016/j.amjmed.2016.03.042 .
  14. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ . 6 . A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation . American Heart Journal . 153 . 1 . 66.e9–66.16 . January 2007 . 17174640 . 10.1016/j.ahj.2006.10.010 .
  15. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E . 6 . Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial . Circulation . 116 . 25 . 2923–2932 . December 2007 . 18056526 . 10.1161/CIRCULATIONAHA.107.740324 . 8226182 .
  16. FDA Announces New Boxed Warning on Plavix: Alerts patients, health care professionals to potential for reduced effectiveness . March 12, 2010 . U.S. Food and Drug Administration (FDA) . March 13, 2010 . March 15, 2010 . https://web.archive.org/web/20100315133622/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm204253.htm . dead .
  17. Web site: FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug . U.S. Food and Drug Administration (FDA) . March 12, 2010 . March 13, 2010 .
  18. Ruff CT, Giugliano RP, Antman EM, Murphy SA, Lotan C, Heuer H, Merkely B, Baracioli L, Schersten F, Seabro-Gomes R, Braunwald E, Wiviott SD . 6 . Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world . International Journal of Cardiology . 155 . 3 . 424–429 . March 2012 . 21093072 . 10.1016/j.ijcard.2010.10.040 .
  19. Silvano M, Zambon CF, De Rosa G, Plebani M, Pengo V, Napodano M, Padrini R . A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty . Journal of Thrombosis and Thrombolysis . 31 . 2 . 233–234 . February 2011 . 21088983 . 10.1007/s11239-010-0533-x . 20617890 .
  20. Warlo EM, Arnesen H, Seljeflot I . A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease . Thrombosis Journal . 17 . 1 . 11 . December 2019 . 31198410 . 6558673 . 10.1186/s12959-019-0197-5 . free .
  21. Web site: O'Riordan M . Switching from clopidogrel to prasugrel further reduces platelet function. TheHeart.org. 1 April 2011.
  22. Web site: Efient (prasugrel) tablets: Highlights of prescribing information . https://web.archive.org/web/20120131041933/http://pi.lilly.com/us/effient.pdf . 31 January 2012 . 2011 . Eli Lilly .
  23. Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ . 6 . Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450 . Drug Metabolism and Disposition . 34 . 4 . 600–607 . April 2006 . 16415119 . 10.1124/dmd.105.007989 . 1698598 .
  24. Kurokawa T, Fukami T, Yoshida T, Nakajima M . Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog . Drug Metabolism and Disposition . 44 . 3 . 409–416 . March 2016 . 26718653 . 10.1124/dmd.115.068221 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Prasugrel".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.